This technology has identified an enzyme-iron interaction that can regulate adipose tissue browning, altering fat content to treat obesity, type 2 diabetes, and cachexia.
The obesity pandemic continues to escalate globally, contributing to a surge in chronic health conditions. Current weight loss drugs target the GLP-1 pathway to reduce appetite, but have been reported to induce severe adverse effects, such as nausea and vomiting. Furthermore, these drugs primarily regulate weight through food intake, failing to target underlying metabolomic mechanisms of fat gain or loss in diseases such as obesity and cachexia.
This technology identifies methionine sulfoxide reductase (MSRA) as a target enzyme for regulating fat. When stabilized by interacting with iron, MRSA promotes adipose tissue browning, resulting in increased energy expenditure and fat loss. Targeting this interaction can therefore alter fat content to treat and prevent diseases such as obesity, type II diabetes, and cachexia.
Patent Pending
